PD-L1 and TERT Mutations Flag Aggressive Thyroid Cancers for Immunotherapy
A 73-patient study finds PD-L1 expression and TERT mutations identify high-grade thyroid cancers most likely to benefit from checkpoint inhibitor therapy.
Summary
Researchers at a major Italian academic center studied 73 patients with aggressive thyroid cancers — including poorly differentiated, high-grade differentiated, and anaplastic types — to determine which molecular markers predict outcomes and guide treatment. They found that PD-L1 protein expression was present in nearly a third of cases, concentrated in anaplastic and high-grade differentiated tumors but absent in poorly differentiated ones. BRAF V600E mutations appeared in 19 cases and TERT promoter mutations in 16. Crucially, TERT mutations correlated strongly with overall survival, making them a meaningful prognostic tool. PD-L1 positivity, while not independently prognostic, identifies a subset of patients who may respond to immune checkpoint inhibitor drugs — an increasingly important treatment avenue for cancers with few effective options.
Detailed Summary
Thyroid cancer is usually a manageable disease, but a small subset of cases — poorly differentiated thyroid carcinoma (PDTC), anaplastic thyroid carcinoma (ATC), and the newly classified differentiated high-grade thyroid carcinoma (DHGTC) — carry a far grimmer prognosis. These aggressive variants have limited treatment options, making the identification of actionable biomarkers critically important.
This institutional study from Fondazione Policlinico Universitario Agostino Gemelli in Rome analyzed 73 patients diagnosed between 2010 and 2023 with PDTC (35 cases), DHGTC (8 cases), and ATC (30 cases). The team evaluated expression of PD-L1, a key immune checkpoint protein, alongside BRAF V600E and TERT promoter mutations, correlating findings with clinicopathological features including lymph node involvement, vascular invasion, and tumor stage.
PD-L1 expression was detected in 24 of 73 cases — notably in 5 DHGTC and 19 ATC patients, but in zero PDTC cases. This differential expression is clinically significant: it suggests that immune checkpoint inhibitors, which target the PD-L1/PD-1 axis, may be most relevant for ATC and DHGTC patients. BRAF V600E mutations were found in 19 cases and TERT promoter mutations in 16. TERT mutations demonstrated a strong correlation with overall survival, reinforcing their value as a prognostic biomarker in high-grade thyroid malignancy.
The findings align with growing evidence supporting immunotherapy in aggressive thyroid cancers and provide a molecular rationale for patient stratification. The WHO 2022 reclassification that introduced DHGTC as a distinct entity is validated here by its unique PD-L1 expression pattern.
Caveats include the retrospective single-institution design, relatively small cohort size, and the fact that this summary is based on the abstract only. Nonetheless, the data support routine PD-L1 and TERT testing in high-grade thyroid carcinoma to guide therapeutic decisions.
Key Findings
- PD-L1 was expressed in 19/30 ATC and 5/8 DHGTC cases, but in zero PDTC cases.
- TERT promoter mutations correlated strongly with overall survival across all high-grade thyroid subtypes.
- BRAF V600E mutations were identified in 19 of 73 aggressive thyroid cancer cases.
- PD-L1 positivity identifies patients most likely to benefit from immune checkpoint inhibitor therapy.
- WHO 2022's new DHGTC category shows a distinct molecular profile supporting its classification.
Methodology
Retrospective single-institution cohort study of 73 patients diagnosed with PDTC, DHGTC, or ATC at a major Italian academic medical center from January 2010 to December 2023. Cases were analyzed for PD-L1 immunohistochemical expression and BRAF V600E and TERT promoter mutation status, correlated with clinicopathological variables including nodal involvement, vascular invasion, and pathological stage.
Study Limitations
This is a retrospective, single-institution study with a relatively small cohort of 73 patients, limiting generalizability. The summary is based on the abstract only, so full methodology, statistical details, and survival curves could not be reviewed. Selection bias inherent to institutional series may affect the reported mutation frequencies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.